domingo, 4 de febrero de 2018

[Consensus on clinical diagnosis, treatment and pedigree management of hereditary colorectal cancer in China]. - PubMed - NCBI

[Consensus on clinical diagnosis, treatment and pedigree management of hereditary colorectal cancer in China]. - PubMed - NCBI



 2018 Jan 23;40(1):64-77. doi: 10.3760/cma.j.issn.0253-3766.2018.01.013.

[Consensus on clinical diagnosis, treatment and pedigree management of hereditary colorectal cancer in China].

[Article in Chinese; Abstract available in Chinese from the publisher]

Abstract

Hereditary colorectal cancer can be divded into two categories based on the presence or absence of polyps. The first category is characterized by the development of polyposis, which includes familial adenomatous polyposis (FAP); The second category is nonpolyposis colorectal cancer, which is represented by Lynch syndrome. "Consensus on clinical diagnosis, treatment and pedigree management of hereditary colorectal cancer in China" developed by the Genetics Group of the Committee of Colorectal Cancer, Chinese Anti-cancer Association, is composed of three sections, including hereditary nonpolyposis syndrome, polyposis syndrome as well as genetic evaluation of hereditary colorectal cancer. The consensus aims to provide recommendations on management of the respective hereditary syndromes in terms of definition, clinical and pathological features, diagnostic standards, treatment, and follow-ups. In addition to describing diagnostic and treatment strategies, prophylactic treatment as well as genetic screening and pedigree monitoring is highly recommended. Through the establishment of this expert consensus, we hope to promote better understanding of hereditary colorectal cancer for clinicians and encourage standardized treatment through multidisciplinery approaches, eventually improving clinical treatment and pedigree management of hereditary colorectal cancer in China.

KEYWORDS:

Familial adenomatous polyposis; Genetic screening; Hereditary colorectal cancer; Lynch syndrome

PMID:
 
29365422

No hay comentarios:

Publicar un comentario